Literature DB >> 19446624

pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.

Pierre Simard1, Jean-Christophe Leroux.   

Abstract

A promising avenue in cancer therapy using liposomal formulations is the combination of site-specific delivery with triggered drug release. The use of trigger mechanisms in liposomes could be relevant for drugs susceptible to lysosomal hydrolytic/enzymatic degradation. Here, we propose a polymeric pH-sensitive liposome system that is designed to release its content inside the endosomes through a polymer structural change following receptor-mediated internalization. Specifically, pH-sensitive immunoliposomes (ILs) were obtained by including a terminally alkylated copolymer of N-isopropylacrylamide (NIPAM) in the liposome bilayer and by coupling the anti-CD33 monoclonal antibody to target leukemic cells. In vitro release of encapsulated fluorescent probes and cytosine arabinoside (ara-C) revealed that pH-sensitivity of the vector was retained in the presence of the antibody upon incubation in plasma. Flow cytometry and confocal microscopy analyses demonstrated that the pH-sensitive ILs were efficiently internalized by various CD33+ leukemic cell lines while limited interaction was found for liposomes decorated with an isotype-matched control antibody. Finally, the pH-sensitive ILs-CD33 formulation exhibited the highest cytotoxicity against HL60 cells, confirming the role of the NIPAM copolymer in promoting the escape of intact ara-C in the endosomes. These results suggest that this pH-sensitive liposomal formulation could be beneficial in the treatment of acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446624     DOI: 10.1016/j.ijpharm.2009.05.013

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.

Authors:  Hong Li; Songlin Xu; Jishan Quan; Bryant C Yung; Jiuxia Pang; Chenguang Zhou; Young-Ah Cho; Mengzi Zhang; Shujun Liu; Natarajan Muthusamy; Kenneth K Chan; John C Byrd; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Mol Pharm       Date:  2015-04-28       Impact factor: 4.939

2.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 3.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

4.  Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.

Authors:  Arif Khan; Masood A Khan; Ahmed N Aljarbou; Yousef H Aldebasi; Khaled S Allemailem; Mohammed A Alsahli; Shamshir Khan; Abdulmohsen M Alruwetei
Journal:  Int J Nanomedicine       Date:  2020-08-05

Review 5.  Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Authors:  Xue-Qing Zhang; Xiaoyang Xu; Nicolas Bertrand; Eric Pridgen; Archana Swami; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

Review 6.  Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.

Authors:  Xiao Huang; Hai Lin; Feng Huang; Yuning Xie; Ka Hong Wong; Xiaoyu Chen; Dongyue Wu; Aiping Lu; Zhijun Yang
Journal:  Dose Response       Date:  2019-12-11       Impact factor: 2.658

7.  Complexes containing cationic and anionic pH-sensitive liposomes: comparative study of factors influencing plasmid DNA gene delivery to tumors.

Authors:  Yan Chen; Ji Sun; Ying Lu; Chun Tao; Jingbin Huang; He Zhang; Yuan Yu; Hao Zou; Jing Gao; Yanqiang Zhong
Journal:  Int J Nanomedicine       Date:  2013-04-22

8.  Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.

Authors:  Xinlong Zang; Huaiwei Ding; Xiufeng Zhao; Xiaowei Li; Zhouqi Du; Haiyang Hu; Mingxi Qiao; Dawei Chen; Yuihui Deng; Xiuli Zhao
Journal:  Int J Nanomedicine       Date:  2016-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.